Benzinga | Feb 25, 2021 06:20AM EST

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $29

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $33 to $29.